Table 2 Treatment patterns at baseline for all patients and stratified by prompt or delayed FF/UMEC/VI initiation
|  | Total (N = 1599) | Prompt (0–30 days) (N = 393) | Delayed (31–180 days) (N = 1206) |
|---|---|---|---|
Number of respiratory therapy classes at baseline | Â | Â | Â |
 Mean (SD) | 3.0 (1.22) | 3.1 (1.14) | 3.0 (1.24) |
Class of respiratory therapy at baseline*, n (%) | Â | Â | Â |
 SABA | 1426 (89.2) | 358 (91.1) | 1068 (88.6) |
 MITT | 1005 (62.9) | 259 (65.9) | 746 (61.9) |
 ICS/LABA | 952 (59.5) | 233 (59.3) | 719 (59.6) |
 LAMA | 814 (50.9) | 197 (50.1) | 617 (51.2) |
 LABA/LAMA | 313 (19.6) | 101 (25.7) | 212 (17.6) |
 Methylxanthine | 98 (6.1) | 27 (6.9) | 71 (5.9) |
 ICS/SABA | 73 (4.6) | 14 (3.6) | 59 (4.9) |
Inhaled therapy regimen immediately prior to index†, n (%) |  |  |  |
 MITT | 731 (45.7) | 168 (42.8) | 563 (46.7) |
 ICS, LABA, or ICS/LABA | 352 (22.0) | 75 (19.1) | 277 (23.0) |
 LABA/LAMA | 257 (16.1) | 91 (23.2) | 166 (13.8) |
 LAMA | 181 (11.3) | 49 (12.5) | 132 (11.0) |
 None of the above regimens | 78 (4.9) | 10 (2.5) | 68 (5.6) |